MeiraGTx Holdings (MGTX) Total Non-Current Liabilities (2017 - 2025)
MeiraGTx Holdings (MGTX) reported Total Non-Current Liabilities of $248.8 million for Q4 2025, up 24.97% on a YoY basis from $199.1 million in Q4 2024, and up 8.82% quarter-over-quarter from $228.7 million in Q3 2025.
MeiraGTx Holdings (MGTX) Total Non-Current Liabilities (2017 - 2025) Analysis & Trends
MeiraGTx Holdings has reported Total Non-Current Liabilities for 9 years, with the latest figure at $248.8 million in Q4 2025.
- For the quarter ending Q4 2025, Total Non-Current Liabilities rose 24.97% year-over-year to $248.8 million; the trailing twelve-month figure through Dec 2025 stood at $248.8 million (up 24.97% YoY), and the FY2025 full-year result was $248.8 million, up 24.97% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $248.8 million, up from $228.7 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $248.8 million in Q4 2025, with the low at $108.4 million in Q2 2022.
- Historically, Total Non-Current Liabilities has averaged $173.0 million across 5 years, with a median of $184.7 million in 2023.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities fell 9.03% — and 2023, when it soared 70.16%.
- MeiraGTx Holdings' Total Non-Current Liabilities stood at $132.7 million in 2021, then jumped by 49.47% to $198.3 million in 2022, then declined by 6.13% to $186.2 million in 2023, then climbed by 6.95% to $199.1 million in 2024, then climbed by 24.97% to $248.8 million in 2025.
- The last three Total Non-Current Liabilities figures came in at $248.8 million (Q4 2025), $228.7 million (Q3 2025), and $194.3 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | MeiraGTx Holdings | 910.47 Mn | 844.54 Mn | 74.89 Mn | 248.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 248.82 Mn |
| Sep 30, 2025 | 228.66 Mn |
| Jun 30, 2025 | 194.30 Mn |
| Mar 31, 2025 | 189.57 Mn |
| Dec 31, 2024 | 199.10 Mn |
| Sep 30, 2024 | 200.87 Mn |
| Jun 30, 2024 | 184.12 Mn |
| Mar 31, 2024 | 185.06 Mn |
| Dec 31, 2023 | 186.17 Mn |
| Sep 30, 2023 | 172.99 Mn |
| Jun 30, 2023 | 184.44 Mn |
| Mar 31, 2023 | 195.68 Mn |
| Dec 31, 2022 | 198.32 Mn |
| Sep 30, 2022 | 176.66 Mn |
| Jun 30, 2022 | 108.39 Mn |
| Mar 31, 2022 | 124.30 Mn |
| Dec 31, 2021 | 132.68 Mn |
| Sep 30, 2021 | 113.58 Mn |
| Jun 30, 2021 | 119.15 Mn |
| Mar 31, 2021 | 117.03 Mn |